<DOC>
	<DOCNO>NCT02445976</DOCNO>
	<brief_summary>The goal clinical study determine safety efficacy VT-464 , lyase-selective inhibitor CYP17 androgen receptor antagonist , patient castration-resistant prostate cancer ( CRPC ) previously treat enzalutamide abiraterone .</brief_summary>
	<brief_title>Once-daily Oral VT-464 Patients With Castration-Resistant Prostate Cancer Progressing Enzalutamide Abiraterone .</brief_title>
	<detailed_description>This phase 2 clinical trial VT-464 ( oral , potent lyase-selective CYP17 inhibitor ) chemotherapy-naïve men castration-resistant prostate cancer ( CRPC ) progress enzalutamide abiraterone . A maximal 148 patient Simon two-stage design use assess treatment efficacy . The study conduct four different clinical cohort separate prior exposure enzalutamide abiraterone acetate , prior response agent ( 37 patient per cohort ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients must document histological cytological evidence adenocarcinoma prostate . 2 . Patients must receive enzalutamide abiraterone CRPC . Patients receive combination enzalutamide/abiraterone combination ARN509/abiraterone part ongoing clinical trial allow include `` Prior Abiraterone '' arm study . Prior treatment sequential enzalutamideabiraterone abirateroneenzalutamide allow . Prior treatment firstgeneration AR antagonist ( i.e. , bicalutamide , nilutamide , flutamide ) abiraterone enzalutamide allow . 3 . Patients must demonstrate disease progression enzalutamide and/or abiraterone . Progressive disease define one following : A rise PSA two successive determination least one week apart PSA level ≥2ng/ml . Softtissue progression define RECIST 1.1 Bone disease progression define PCWG2 two new lesion bone scan 4 . Patients must minimum serum PSA level ≥2 ng/ml rise base PCWG2 criterion . 5 . Patients must ≥18 year age . 6 . Patients must castrate level testosterone ( &lt; 50 ng/dl [ 1.74 nmol/l ] ) . 7 . Patients must undergo orchiectomy , LHRH agonists antagonist , least 3 month prior drug initiation . Patients LHRH agonists/antagonists must remain agent duration study . 8 . Patients must ECOG Performance Score 01 . 9 . Patients must adequate hematopoietic function evidence : WBC ≥3,000/µl ANC ≥1,500/µl Platelet count ≥100,000/µl HGB ≥10 g/dl 10 . Patients must adequate hepatic function evidence AST/ALT level &lt; 3X ULN bilirubin level &lt; 2.0 mg/dl . 11 . Patients must adequate renal function evidence serum creatinine &lt; 2.0 mg/dl . 12 . Patients must K+ &gt; 3.5 mEq/l . 13 . Patients legal representative must able provide write informed consent . 14 . Patients must discontinue enzalutamide abiraterone/prednisolone ≥4 week prior study drug initiation . 15 . Patients partner childbearing potential must willing use least two form effective birth control ( one form must barrier method ) treatment period 90 day last dose VT464 . Patients must also agree donate sperm 90 day follow last dose VT464 . Exclusion Criteria 1 . 1 . Patients receive prior cytotoxic chemotherapy castrationresistant prostate cancer . Prior docetaxel castrationsensitive disease permit . 2 . Patients receive TAK700 ( Orteronel® ) , TOK001 ( Galeterone® ) , ARN509 therapeutic investigational product direct towards androgen receptor ( AR ) androgen biosynthesis . Patients receive ARN509 combination abiraterone part clinical trial allow . 3 . Patients receive ketoconazole , aminoglutethimide , highdose estrogen CRPC . 4 . Patients complete sipuleucelT ( Provenge ® ) treatment within 30 day study drug initiation . 5 . Patients 5 alpha reductase inhibitor finasteride ( PROSCAR® , PROPECIA® ) , dutasteride ( AVODART® ) within 3 month study drug initiation . 6 . Patients require pharmacologic replacement dos systemic corticosteroid receive systemic corticosteroid within 30 day study drug initiation ; use topical , inhaled ophthalmic steroid permit . 7 . Patients receive therapeutic investigational agent within 2 week study drug initiation . 8 . Patients receive palliative radiotherapy within 4 week study drug initiation . 9 . Patients receive herbal product alternative therapy may decrease PSA level may hormonal antiprostate cancer activity ( e.g. , saw palmetto , PCSPES , PCHOPE , St. John 's wort , selenium supplement , grape seed extract , etc . ) within 4 week study drug initiation plan initiate treatment products/alternative therapy entire duration study . 10 . Patients active CNS metastasis prostate cancer . Patients treat epidural disease eligible enroll . Patients treat brain metastasis include long &gt; 4 week elapse since last treatment ( radiotherapy surgery ) brain metastasis , patient neurologically radiographically stable , receive corticosteroid brain metastasis . Patients untreated brain metastasis exclude . Brain imaging ( CT MRI ) require baseline brain metastasis clinically suspect . 11 . Patients history adrenal insufficiency . Patients receive systemic corticosteroid &gt; 2 week within 6 month study drug initiation ( include receive prednisolone abiraterone ) must adrenal insufficiency rule morning plasma cortisol concentration ≥500 nmol/l plasma cortisol response ACTH stimulation test deem clinically normal . 12 . Patients history within last 3 year another invasive malignancy ( exclude nonmelanoma skin cancer ) . 13 . Patients QTcF interval &gt; 470 msec ; Screening ECG QTcF interval &gt; 470 msec , may repeat , repeat ≤470 msec , patient may enrol . 14 . Patients history clinically significant cardiac arrhythmia include ventricular tachycardia , ventricular fibrillation , torsades de pointes second degree third degree atrioventricular heart block without permanent pacemaker place . Patients resolve ratecontrolled atrial fibrillation/atrial flutter allow . 15 . Patients NYHA Class III IV congestive heart failure , unstable angina , myocardial infarction/acute coronary syndrome within precede 6 month . 16 . Patients diabetes mellitus 2 episode diabetic ketoacidosis precede 12 month . 17 . Inadequately control hypertension ( define blood pressure &gt; 150mmHg systolic and/or &gt; 100 mmHg diastolic despite antihypertensive medication ) history hypertensive crisis hypertensive encephalopathy . 18 . Patients history seizure within past 2 year require prophylactic antiseizure medication exclude . 19 . History loss consciousness transient ischemic attack within 12 month study drug initiation . 20 . Patients know active HIV , Hepatitis B , Hepatitis C infection . 21 . Patients medical , psychiatric , social condition , include substance abuse , opinion Investigator would preclude safe participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>mCRPC</keyword>
	<keyword>metastatic</keyword>
	<keyword>castration-resistant prostate cancer</keyword>
</DOC>